Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Palombo

Anesthesiology Richmond, VA Medical Doctor

NPI 1336105972 CMS profile 913389

9101 Stony Point Dr, Richmond, VA 23235

Open in the dashboard

General payments

$5,659

242 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Palombo of Richmond, VA is reported in the CMS Open Payments database as having received $5,659 across 242 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,669 68
2024 General $1,890 75
2023 General $1,098 47
2022 General $502 24
2021 General $322 18
2020 General $110 6
2019 General $67 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Palombo
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to David Palombo were reported at $1,669. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year David Palombo Anesthesiology median Middle half National median
2019 $67 $72 $23–$151 $163
2020 $110 $36 $17–$120 $114
2021 $322 $49 $21–$135 $132
2022 $502 $52 $22–$144 $149
2023 $1,098 $53 $23–$143 $160
2024 $1,890 $55 $25–$150 $164
2025 $1,669 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dendreon Pharmaceuticals LLC $1,086 37 payments
  2. Sumitomo Pharma America, Inc. $617 26 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $548 22 payments
  4. Endo USA, Inc. $438 20 payments
  5. Urogen Pharma, Inc. $433 15 payments
  6. Blue Earth Diagnostics Limited $325 13 payments
  7. Janssen Biotech, Inc. $257 12 payments
  8. Novartis Pharmaceuticals Corporation $250 13 payments
  9. Endo Pharmaceuticals Inc. $229 14 payments
  10. Progenics Pharmaceuticals, Inc. $219 12 payments
  11. Other $1,257 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,659 242 payments
Products named General payments · program years 2019–2025
  1. PROVENGE $1,086 37 payments
  2. GEMTESA $689 30 payments
  3. XIAFLEX $604 31 payments
  4. Xofigo $548 22 payments
  5. Nubeqa $510 20 payments
  6. AVEED $479 25 payments
  7. JELMYTO $350 12 payments
  8. POSLUMA $278 11 payments
  9. PLUVICTO $250 13 payments
  10. ERLEADA $235 11 payments
  11. Other $1,954 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$54,045

Medicare's payments for the services billed

Medicare patients

869

Average age 74

Services billed

920

238 women, 631 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Cancer 44%
Arthritis 40%
Diabetes 26%
Ischemic heart disease 25%
Chronic kidney disease 19%
Atrial fibrillation 14%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $330
$330 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $212
$212 — —
XIAFLEX
  • Endo USA, Inc. $158
  • Endo Pharmaceuticals Inc. $28
$186 — —
JELMYTO
  • UROGEN PHARMA, INC. $144
$144 — —
PLUVICTO
  • Novartis Pharmaceuticals Corporation $132
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

242 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record